What is the study about?
Hot flushes affect 70% of menopausal women, with up to 20% of these women describing them as ‘intolerable’. Furthermore hot flushes can last up to 20 years, therefore having a significant and long-lasting effect on quality of life. Hormone Replacement Therapy (HRT) is the mainstay of treatment but confers an increased risk of breast cancer, stroke and thromboembolism. Therefore current guidelines recommend a limited duration of therapy and in several women HRT cannot be prescribed. Some other medications are available to prescribe but these are less effective than HRT. This highlights an unmet need to develop non-hormonal alternative treatments for menopausal flushing.
Neurokinin B (NKB) is a naturally occurring hormone found in healthy people, which helps to regulate the levels of sex hormones (reproductive hormones) in humans. Recent studies in humans show that NKB signalling also controls menopausal hot flushes. We therefore think that blocking the NK3 receptor (the primary receptor for NKB) could be a new treatment approach for menopausal hot flushes.NK3R Study – Published